AR119424A1 - Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp - Google Patents
Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parpInfo
- Publication number
- AR119424A1 AR119424A1 ARP200102008A ARP200102008A AR119424A1 AR 119424 A1 AR119424 A1 AR 119424A1 AR P200102008 A ARP200102008 A AR P200102008A AR P200102008 A ARP200102008 A AR P200102008A AR 119424 A1 AR119424 A1 AR 119424A1
- Authority
- AR
- Argentina
- Prior art keywords
- oxo
- quinoxaline
- parp inhibitors
- alkyl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos derivados de oxo-naftiridina y de 3-oxo-quinoxalina como inhibidores de PARP, composiciones farmacéuticas que los comprenden y el uso de los mismos para el tratamiento de cáncer, en particular el cáncer que es deficiente en la ruta de reparación de DSB de ADN dependiente de HR y células cancerosas deficientes en BCRA1 y BCRA2. Reivindicación 1: Un compuesto de fórmula (1) en la que: X¹ y X² se seleccionan cada uno independientemente de N y C(H), X³ se selecciona independientemente de N y C(R⁴), en el que R⁴ es H o flúor, R¹ es alquilo C₁₋₄ o fluoroalquilo C₁₋₄, R² se selecciona independientemente de H, halo, alquilo C₁₋₄ y fluoroalquilo C₁₋₄, y R³ es H o alquilo C₁₋₄, o una sal farmacéuticamente aceptable del mismo con la condición de que: cuando X¹ es N, entonces X² es C(H) y X³ es C(R⁴), cuando X² es N, entonces X¹ = C(H) y X³ es C(R⁴), y cuando X³ es N, entonces X¹ y X² son ambos C(H).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876065P | 2019-07-19 | 2019-07-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119424A1 true AR119424A1 (es) | 2021-12-15 |
Family
ID=71728735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102008A AR119424A1 (es) | 2019-07-19 | 2020-07-17 | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US11325906B2 (es) |
| EP (2) | EP4529952A3 (es) |
| JP (1) | JP7641944B2 (es) |
| KR (1) | KR20220035941A (es) |
| CN (1) | CN114144413B (es) |
| AR (1) | AR119424A1 (es) |
| AU (1) | AU2020318599B2 (es) |
| BR (1) | BR112022000534A2 (es) |
| CA (1) | CA3145644A1 (es) |
| CL (1) | CL2022000110A1 (es) |
| CO (1) | CO2022001590A2 (es) |
| CR (1) | CR20220070A (es) |
| DK (1) | DK3999506T3 (es) |
| DO (1) | DOP2022000006A (es) |
| EC (1) | ECSP22012826A (es) |
| ES (1) | ES3021859T3 (es) |
| FI (1) | FI3999506T3 (es) |
| HR (1) | HRP20250373T1 (es) |
| HU (1) | HUE071067T2 (es) |
| IL (1) | IL289534B2 (es) |
| JO (1) | JOP20220008A1 (es) |
| LT (1) | LT3999506T (es) |
| MA (1) | MA57972B1 (es) |
| MX (1) | MX2022000711A (es) |
| MY (1) | MY208549A (es) |
| NZ (1) | NZ784224A (es) |
| PE (1) | PE20221339A1 (es) |
| PH (1) | PH12022550098A1 (es) |
| PL (1) | PL3999506T3 (es) |
| PT (1) | PT3999506T (es) |
| RS (1) | RS66682B1 (es) |
| SI (1) | SI3999506T1 (es) |
| SM (1) | SMT202500146T1 (es) |
| TW (1) | TWI837403B (es) |
| UA (1) | UA129093C2 (es) |
| UY (1) | UY38793A (es) |
| WO (1) | WO2021013735A1 (es) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019222272A1 (en) | 2018-05-14 | 2019-11-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| CA3138197A1 (en) | 2019-05-14 | 2020-11-19 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4058464A1 (en) | 2019-11-13 | 2022-09-21 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| IL301921A (en) | 2020-10-09 | 2023-06-01 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate and parp1 selective inhibitor |
| CA3214408A1 (en) | 2021-03-23 | 2022-09-29 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| US20240208969A1 (en) * | 2021-04-12 | 2024-06-27 | Impact Therapeutics (Shanghai), Inc. | Substituted fused bicyclic compounds as parp inhibitors and the use thereof |
| TW202309025A (zh) | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| EP4328224A4 (en) * | 2021-04-22 | 2025-06-18 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | PARP INHIBITOR WITH PIPERAZINE STRUCTURE, MANUFACTURING METHOD THEREOF AND PHARMACEUTICAL USE THEREOF |
| CN115232121B (zh) * | 2021-04-23 | 2023-08-29 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
| CN115702156A (zh) * | 2021-04-23 | 2023-02-14 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| CA3215823A1 (en) * | 2021-04-23 | 2022-10-27 | Peng Gao | Heterocyclic derivative inhibitor and preparation method therefor and application thereof |
| WO2022222966A1 (zh) * | 2021-04-23 | 2022-10-27 | 成都百裕制药股份有限公司 | 一种选择性parp1抑制剂及其应用 |
| IL308104A (en) | 2021-05-03 | 2023-12-01 | Nuvation Bio Inc | Nuclear hormone receptor-targeted compounds against cancer |
| AU2022276986B2 (en) * | 2021-05-18 | 2025-07-03 | Onconic Therapeutics Inc. | Parp inhibitor-resistant cancer therapeutic agent |
| MX2023013890A (es) | 2021-05-24 | 2023-12-11 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto heterociclico que contiene nitrogeno, metodo de preparacion del mismo y aplicacion del mismo en medicamentos. |
| KR20240021884A (ko) * | 2021-06-16 | 2024-02-19 | 리페어 세라퓨틱스 인크. | 암을 치료하기 위한 parp 억제제와 조합된 atr 억제제의 용도 |
| US20240366584A1 (en) | 2021-06-21 | 2024-11-07 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| EP4392425A4 (en) * | 2021-08-27 | 2025-09-03 | Impact Therapeutics Shanghai Inc | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THEIR USE |
| CN118119618A (zh) * | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| US20240391937A1 (en) | 2021-09-30 | 2024-11-28 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| CN118019740A (zh) * | 2021-09-30 | 2024-05-10 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| EP4410792A4 (en) | 2021-09-30 | 2025-12-03 | Xizang Haisco Pharmaceutical Co Ltd | NITROGEN-CONTAINS HETEROCYCLIC DERIVATIVE FOR USE AS A PARP INHIBITOR AND ITS USE |
| PE20241129A1 (es) | 2021-10-01 | 2024-05-24 | Xinthera Inc | Inhibidores de parp1 de azetidina y pirrolidina y usos de estos |
| WO2023061406A1 (zh) * | 2021-10-12 | 2023-04-20 | 微境生物医药科技(上海)有限公司 | 含三并环结构的parp抑制剂、及其制备方法和医药用途 |
| WO2023066363A1 (zh) * | 2021-10-22 | 2023-04-27 | 海思科医药集团股份有限公司 | Parp-1降解剂及其用途 |
| MX2024006039A (es) | 2021-11-18 | 2024-06-04 | Astrazeneca Uk Ltd | Combinacion de conjugado de anticuerpo-farmaco e inhibidor selectivo de poli(adenosina-5'-difosfato-ribosa) polimerasa 1 (parp1). |
| TWI842210B (zh) * | 2021-11-19 | 2024-05-11 | 大陸商成都百裕製藥股份有限公司 | 選擇性parp1抑制劑及其應用 |
| WO2023096915A1 (en) * | 2021-11-24 | 2023-06-01 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| WO2023109521A1 (zh) * | 2021-12-17 | 2023-06-22 | 凯复(苏州)生物医药有限公司 | Parp抑制剂、包含其的药物组合物及其用途 |
| IL313661A (en) * | 2021-12-21 | 2024-08-01 | Astrazeneca Ab | Methods of treating brain tumours and neuroblastomas |
| TW202332438A (zh) * | 2021-12-22 | 2023-08-16 | 美商思諾維新醫藥公司 | Ｐａｒｐ１抑制劑 |
| WO2023133413A1 (en) * | 2022-01-07 | 2023-07-13 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| EP4464704A4 (en) * | 2022-01-13 | 2025-09-03 | Acerand Therapeutics Hong Kong Ltd | DERIVATIVE CONTAINING A PIPERAZINO RING, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR ITS PREPARATION AND USE THEREOF |
| WO2023138541A1 (zh) * | 2022-01-20 | 2023-07-27 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| KR102866565B1 (ko) * | 2022-01-21 | 2025-10-02 | 신테라, 인크. | Parp1 저해제 및 이의 용도 |
| AU2023213731A1 (en) * | 2022-01-27 | 2024-08-15 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| KR20240139603A (ko) * | 2022-01-28 | 2024-09-23 | 신테라, 인크. | Parp1 저해제 및 이의 용도 |
| CN116693501B (zh) * | 2022-02-10 | 2025-12-19 | 康百达（四川）生物医药科技有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| TW202348252A (zh) | 2022-02-16 | 2023-12-16 | 英商梅迪繆思有限公司 | 用治療性結合分子治療癌症的組合療法 |
| CN118660888A (zh) * | 2022-03-01 | 2024-09-17 | 杭州领业医药科技有限公司 | Azd5305的晶型及其制备方法和用途 |
| EP4493551A1 (en) | 2022-03-14 | 2025-01-22 | Slap Pharmaceuticals LLC | Multicyclic compounds |
| CA3254948A1 (en) | 2022-04-07 | 2023-10-12 | Astrazeneca Ab | Polytherapy for the treatment of cancer |
| KR20240170958A (ko) | 2022-04-07 | 2024-12-05 | 아스트라제네카 아베 | 암 치료를 위한 병용 요법 |
| AU2023250031A1 (en) | 2022-04-07 | 2024-11-14 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| JP2025517106A (ja) * | 2022-04-28 | 2025-06-03 | ニンボー・ニューベイ・テクノロジー・ディベロップメント・カンパニー・リミテッド | Ｐａｒｐ１阻害剤としての化合物 |
| WO2023212219A1 (en) | 2022-04-28 | 2023-11-02 | Xinthera, Inc. | Tricyclic parp1 inhibitors and uses thereof |
| EP4524142A1 (en) * | 2022-05-07 | 2025-03-19 | Medshine Discovery Inc. | Fluoroquinoxalinone derivative for selectively inhibiting parp1 |
| AU2023275808A1 (en) * | 2022-05-25 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| WO2023242302A1 (en) | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| TW202408509A (zh) * | 2022-07-14 | 2024-03-01 | 大陸商西藏海思科製藥有限公司 | 雜芳基衍生物的藥物組合物及其在醫藥上的應用 |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| CN119365458A (zh) * | 2022-08-25 | 2025-01-24 | 江苏恒瑞医药股份有限公司 | 稠合三环类化合物、其制备方法及其在医药上的应用 |
| WO2024046420A1 (zh) * | 2022-08-31 | 2024-03-07 | 江苏恒瑞医药股份有限公司 | 稠合二环类化合物、其制备方法及其在医药上的应用 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| TW202416977A (zh) * | 2022-09-30 | 2024-05-01 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| CN118139862A (zh) * | 2022-09-30 | 2024-06-04 | 中国医药研究开发中心有限公司 | 含氮杂环类化合物及其医药用途 |
| EP4598924A1 (en) * | 2022-10-06 | 2025-08-13 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| CN120035592A (zh) * | 2022-10-20 | 2025-05-23 | 成都赜灵生物医药科技有限公司 | 并杂环类氘代化合物及其用途 |
| WO2024083201A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| EP4606802A1 (en) * | 2022-10-21 | 2025-08-27 | Shanghai Hansoh Biomedical Co., Ltd. | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof |
| WO2024097775A1 (en) * | 2022-11-02 | 2024-05-10 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4617272A1 (en) * | 2022-11-10 | 2025-09-17 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Fused bicyclic compound |
| JP2025538371A (ja) | 2022-11-23 | 2025-11-28 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 含窒素複素環系化合物の薬用可能な塩、結晶型及び調製方法 |
| JP2025540239A (ja) | 2022-12-06 | 2025-12-11 | アストラゼネカ・アクチエボラーグ | Ｐｏｌｑ阻害剤 |
| EP4620956A1 (en) | 2022-12-23 | 2025-09-24 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| CN117903159A (zh) * | 2022-12-30 | 2024-04-19 | 成都硕德药业有限公司 | 一种内酰胺类衍生物、其制备方法及用途 |
| EP4665399A1 (en) | 2023-02-16 | 2025-12-24 | Astrazeneca AB | Combination therapies for treatment of cancer with therapeutic binding molecules |
| CN116396214A (zh) * | 2023-03-06 | 2023-07-07 | 爱斯特（成都）生物制药股份有限公司 | 一种parp1抑制剂中间体的制备方法 |
| AU2023441454A1 (en) | 2023-03-31 | 2025-11-13 | Astrazeneca Ab | Dosing regiment of azd5305 |
| WO2024231548A1 (en) | 2023-05-11 | 2024-11-14 | Astrazeneca Ab | Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer |
| CN121311226A (zh) | 2023-05-17 | 2026-01-09 | 特沙诺有限公司 | 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途 |
| CN121358725A (zh) | 2023-06-14 | 2026-01-16 | 海思科医药集团股份有限公司 | 双环衍生物parp抑制剂及其用途 |
| GB2630970A (en) * | 2023-06-15 | 2024-12-18 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
| US20250127907A1 (en) * | 2023-06-23 | 2025-04-24 | Stablix, Inc. | Parp inhibitors |
| WO2025090418A1 (en) | 2023-10-23 | 2025-05-01 | Gilead Sciences, Inc. | Parp1 inhibitors and uses thereof |
| WO2025092973A1 (zh) * | 2023-11-03 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | Parp1靶向化合物及其用途 |
| WO2025120513A1 (en) | 2023-12-05 | 2025-06-12 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and blood brain barrier-penetrant parp1 selective inhibitor |
| WO2025153668A1 (en) | 2024-01-19 | 2025-07-24 | Astrazeneca Ab | Pharmaceutical compositions comprising azd5305 |
| CN120398887A (zh) * | 2024-01-31 | 2025-08-01 | 西藏海思科制药有限公司 | 一种双环衍生物parp抑制剂的晶型及其制备方法和应用 |
| WO2025168048A1 (zh) * | 2024-02-08 | 2025-08-14 | 上海璎黎药业有限公司 | 一种三键结构化合物、其药物组合物及其应用 |
| KR20250128449A (ko) | 2024-02-20 | 2025-08-28 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
| WO2025248119A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-(cyclo)alkoxypurine derivatives useful as polq inhibitors |
| WO2025261449A1 (zh) * | 2024-06-19 | 2025-12-26 | 浙江扬厉医药技术有限公司 | 一种parp1抑制剂吡啶酰胺类化合物、中间体及其制备方法 |
| CN118978529A (zh) * | 2024-08-02 | 2024-11-19 | 上海信诺维生物医药有限公司 | 一类含吡啶的杂环化合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT705903E (pt) | 1994-08-12 | 2001-11-30 | Myriad Genetics Inc | Mutacoes no gene de susceptibilidade para o cancro da mama e do ovario ligado a 17q |
| CA2196795C (en) | 1994-08-12 | 2001-04-03 | Mark H. Skolnick | Method for diagnosing a predisposition for breast and ovarian cancer |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| KR101146806B1 (ko) | 2003-03-12 | 2012-05-22 | 메이브릿지 리미티드 | 프탈라지논 유도체 |
| BRPI0416817A (pt) * | 2003-11-20 | 2007-03-06 | Janssen Pharmaceutica Nv | 2-quinolinonas e 2-quinoxalinonas 7-fenilalquila substituìdas como inibidores da poli(adp-ribose)polimerase |
| AU2004295058B9 (en) | 2003-11-20 | 2011-06-30 | Janssen Pharmaceutica N.V. | 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| AU2004295059B2 (en) | 2003-12-05 | 2010-12-16 | Janssen Pharmaceutica N.V. | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| US7652014B2 (en) | 2003-12-10 | 2010-01-26 | Janssen Pharmaceutica | Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors |
| JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | ４−ヘテロアリールメチル置換フタラジノン誘導体 |
| DK2134691T3 (da) | 2007-03-08 | 2012-05-07 | Janssen Pharmaceutica Nv | Quinolinonderivativer som parp- og tank-inhibitorer |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
| WO2010085570A1 (en) * | 2009-01-23 | 2010-07-29 | Takeda Pharmaceutical Company Limited | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors |
| WO2010111626A2 (en) * | 2009-03-27 | 2010-09-30 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| EP2459561A1 (en) | 2009-07-30 | 2012-06-06 | Takeda Pharmaceutical Company Limited | Poly (adp-ribose) polymerase (parp) inhibitors |
| AU2016276806B9 (en) * | 2015-06-09 | 2019-02-21 | Onconic Therapeutics Inc. | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
-
2020
- 2020-07-17 BR BR112022000534A patent/BR112022000534A2/pt unknown
- 2020-07-17 JP JP2022502556A patent/JP7641944B2/ja active Active
- 2020-07-17 JO JOP/2022/0008A patent/JOP20220008A1/ar unknown
- 2020-07-17 CR CR20220070A patent/CR20220070A/es unknown
- 2020-07-17 IL IL289534A patent/IL289534B2/en unknown
- 2020-07-17 FI FIEP20743121.4T patent/FI3999506T3/fi active
- 2020-07-17 KR KR1020227005427A patent/KR20220035941A/ko active Pending
- 2020-07-17 SM SM20250146T patent/SMT202500146T1/it unknown
- 2020-07-17 RS RS20250332A patent/RS66682B1/sr unknown
- 2020-07-17 MY MYPI2022000303A patent/MY208549A/en unknown
- 2020-07-17 EP EP25151532.6A patent/EP4529952A3/en active Pending
- 2020-07-17 WO PCT/EP2020/070306 patent/WO2021013735A1/en not_active Ceased
- 2020-07-17 SI SI202030602T patent/SI3999506T1/sl unknown
- 2020-07-17 NZ NZ784224A patent/NZ784224A/en unknown
- 2020-07-17 EP EP20743121.4A patent/EP3999506B1/en active Active
- 2020-07-17 ES ES20743121T patent/ES3021859T3/es active Active
- 2020-07-17 CA CA3145644A patent/CA3145644A1/en active Pending
- 2020-07-17 MX MX2022000711A patent/MX2022000711A/es unknown
- 2020-07-17 CN CN202080051330.7A patent/CN114144413B/zh active Active
- 2020-07-17 US US16/931,792 patent/US11325906B2/en active Active
- 2020-07-17 UY UY0001038793A patent/UY38793A/es unknown
- 2020-07-17 MA MA57972A patent/MA57972B1/fr unknown
- 2020-07-17 TW TW109124347A patent/TWI837403B/zh active
- 2020-07-17 UA UAA202200512A patent/UA129093C2/uk unknown
- 2020-07-17 AR ARP200102008A patent/AR119424A1/es unknown
- 2020-07-17 PT PT207431214T patent/PT3999506T/pt unknown
- 2020-07-17 PL PL20743121.4T patent/PL3999506T3/pl unknown
- 2020-07-17 HU HUE20743121A patent/HUE071067T2/hu unknown
- 2020-07-17 HR HRP20250373TT patent/HRP20250373T1/hr unknown
- 2020-07-17 PH PH1/2022/550098A patent/PH12022550098A1/en unknown
- 2020-07-17 DK DK20743121.4T patent/DK3999506T3/da active
- 2020-07-17 LT LTEPPCT/EP2020/070306T patent/LT3999506T/lt unknown
- 2020-07-17 PE PE2022000086A patent/PE20221339A1/es unknown
- 2020-07-17 AU AU2020318599A patent/AU2020318599B2/en active Active
-
2022
- 2022-01-17 DO DO2022000006A patent/DOP2022000006A/es unknown
- 2022-01-17 CL CL2022000110A patent/CL2022000110A1/es unknown
- 2022-02-16 CO CONC2022/0001590A patent/CO2022001590A2/es unknown
- 2022-02-17 EC ECSENADI202212826A patent/ECSP22012826A/es unknown
- 2022-04-07 US US17/715,463 patent/US20220227768A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
| CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR106053A1 (es) | Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| CL2018003290A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| AR102204A1 (es) | Compuestos derivados de amino-alquilbenzotiazepinas | |
| AR102094A1 (es) | Inhibidores de proteínas kras con una mutación g12c | |
| AR119018A1 (es) | Inhibidores de proteína quinasas dependientes de adn | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| AR119728A1 (es) | Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2 | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| AR107032A1 (es) | Inhibidores bicíclicos de pad4 | |
| BR112017017135A2 (pt) | inibidores de tgf-beta | |
| AR106138A1 (es) | Compuestos y métodos para inhibir jak | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| AR112283A1 (es) | Uso de derivados de aminoalquilbenzotiazepina | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento |